{'fraction_non_alphanumeric': 0.03497942386831276, 'fraction_numerical': 0.00823045267489712, 'mean_word_length': 5.407894736842105, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cholinesterase inhibitors for Alzheimer's disease: variations in clinical practice in the north‐west of England

In the UK, the National Institute for Health and Clinical Excellence (NICE) is currently reviewing cost‐effectiveness of cholinesterase inhibitors (ChEIs) for Alzheimer's disease (AD) in the NHS. The implementation of the original NICE ( 2001 ) guidance that made these drugs available in the UK was not examined in this review process, and was the objective of this study.